MIMETAS in EU Industry Alliance on Alzheimers

MIMETAS in EU Industry Alliance on Alzheimers

MIMETAS in 6.8 m€ IMI funded EU alliance on Alzheimer's disease to improve understanding of the function of the APOE gene

MIMETAS collaborates in the ADAPTED project with Biogen, Abbvie and Janssen

The IMI project ADAPTED (Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development) project is a major new initiative to investigate an area of Alzheimer's Disease (AD). APOE is well known as a risk factor for developing the disease but precisely how this gene contributes to the risk of developing AD is not known.

Using the expertise of the ADAPTED partners in a range of cutting-edge biological analysis methods, the project will attempt to really unravel the complexities of the APOE gene as well as providing the research community with a new generation of human cell –based tools to mimic and investigate the causes and progression of the disease. MIMETAS collaborates with Biogen, Abbvie and Janssen, as well as academic partners and SMEs.

In this project, MIMETAS will develop neurovascular organs-on-chips models consisting of co-cultures of neurons, astrocytes and endothelial cells that will be relevant to investigate the role APOE in AD development. This model will be applied to improve development of stratified approaches for therapy development.

MIMETAS develops neurovascular models with neurons, astrocytes and endothelial cells to investigate the role APOE in AD
MIMETAS will develop neurovascular organs-on-chips models consisting of co-cultures of neurons, astrocytes and endothelial cells that will be relevant to investigate the role APOE in AD development.
ADAPTED is supported by the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations
ADAPTED receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115975. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations.